A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Single and Multiple Doses of CPD704 Inhalation Suspension in Healthy Chinese Adult Subjects.
Latest Information Update: 31 Dec 2025
At a glance
- Drugs CPD 704 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Beijing Tide Pharmaceutical
Most Recent Events
- 31 Dec 2025 New trial record